MRNA Vaccines Against COVID-19 As Trailblazers for Other Human Infectious Diseases

Overview

Journal Vaccines (Basel)

Date 2025 Jan 8

PMID 39772079

Authors

Rossella Brandi

Alessia Paganelli

Raffaele DAmelio

Paolo Giuliani

Florigio Lista

Simonetta Salemi

Roberto Paganelli

Affiliations

Soon will be listed here.

Abstract

Methods: To date, only two COVID-19 mRNA and one RSV vaccines have been approved. However, several mRNA vaccines are currently under development for the prevention of human viral (influenza, human immunodeficiency virus [HIV], Epstein-Barr virus, cytomegalovirus, Zika, respiratory syncytial virus, metapneumovirus/parainfluenza 3, Chikungunya, Nipah, rabies, varicella zoster virus, and herpes simplex virus 1 and 2), bacterial (tuberculosis), and parasitic (malaria) diseases.

Results: RNA viruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV)-2, HIV, and influenza, are characterized by high variability, thus creating the need to rapidly adapt the vaccines to the circulating viral strain, a task that mRNA vaccines can easily accomplish; however, the speed of variability may be higher than the time needed for a vaccine to be adapted. mRNA vaccines, using lipid nanoparticles as the delivery system, may act as adjuvants, thus powerfully stimulating innate as well as adaptive immunity, both humoral, which is rapidly waning, and cell-mediated, which is highly persistent. Safety profiles were satisfactory, considering that only a slight increase in prognostically favorable anaphylactic reactions in young females and myopericarditis in young males has been observed.

Conclusions: The COVID-19 pandemic determined a shift in the use of RNA: after having been used in medicine as micro-RNAs and tumor vaccines, the new era of anti-infectious mRNA vaccines has begun, which is currently in great development, to either improve already available, but unsatisfactory, vaccines or develop protective vaccines against infectious agents for which no preventative tools have been realized yet.

References

Gebre M, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado N . Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature. 2021; 601(7893):410-414. PMC: 8770133. DOI: 10.1038/s41586-021-04231-6. View

Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N . Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill. 2021; 26(24). PMC: 8212592. DOI: 10.2807/1560-7917.ES.2021.26.24.2100509. View

Pieren D, Kuguel S, Rosado J, Robles A, Rey-Cano J, Mancebo C . Limited induction of polyfunctional lung-resident memory T cells against SARS-CoV-2 by mRNA vaccination compared to infection. Nat Commun. 2023; 14(1):1887. PMC: 10074357. DOI: 10.1038/s41467-023-37559-w. View

Wu N, Wilson I . Influenza Hemagglutinin Structures and Antibody Recognition. Cold Spring Harb Perspect Med. 2019; 10(8). PMC: 7397844. DOI: 10.1101/cshperspect.a038778. View

Underwood A, Solund C, Jacobsen K, Binderup A, Fernandez-Antunez C, Mikkelsen L . Neutralizing antibody and CD8 T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior exposure to SARS-CoV-2. Front Immunol. 2024; 15:1353353. PMC: 10987722. DOI: 10.3389/fimmu.2024.1353353. View

Mariotti S, Venturi G, Chiantore M, Teloni R, De Santis R, Amendola A . Antibodies Induced by Smallpox Vaccination after at Least 45 Years Cross-React with and In Vitro Neutralize Mpox Virus: A Role for Polyclonal B Cell Activation?. Viruses. 2024; 16(4). PMC: 11054675. DOI: 10.3390/v16040620. View

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

Chemaitelly H, Tang P, Hasan M, Almukdad S, Yassine H, Benslimane F . Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021; 385(24):e83. PMC: 8522799. DOI: 10.1056/NEJMoa2114114. View

Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y . Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med. 2021; 385(23):2132-2139. PMC: 8531986. DOI: 10.1056/NEJMoa2110737. View

10.

Zhong L, Zhao Q, Zeng M, Zhang X . Prophylactic vaccines against Epstein-Barr virus. Lancet. 2024; 404(10455):845. DOI: 10.1016/S0140-6736(24)01608-8. View

11.

Engler R, Nelson M, Collins Jr L, Spooner C, Hemann B, Gibbs B . A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. PLoS One. 2015; 10(3):e0118283. PMC: 4368609. DOI: 10.1371/journal.pone.0118283. View

12.

Lin D, Du Y, Xu Y, Paritala S, Donahue M, Maloney P . Durability of XBB.1.5 Vaccines against Omicron Subvariants. N Engl J Med. 2024; 390(22):2124-2127. PMC: 11197991. DOI: 10.1056/NEJMc2402779. View

13.

Schwickert T, Lindquist R, Shakhar G, Livshits G, Skokos D, Kosco-Vilbois M . In vivo imaging of germinal centres reveals a dynamic open structure. Nature. 2007; 446(7131):83-7. DOI: 10.1038/nature05573. View

14.

Jardine J, Kulp D, Havenar-Daughton C, Sarkar A, Briney B, Sok D . HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science. 2016; 351(6280):1458-63. PMC: 4872700. DOI: 10.1126/science.aad9195. View

15.

Jung S, Jeon J, Kim Y, Choe S, Lee S . Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study. Nat Commun. 2024; 15(1):6181. PMC: 11263712. DOI: 10.1038/s41467-024-50656-8. View

16.

Seneff S, Nigh G, Kyriakopoulos A, McCullough P . Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs. Food Chem Toxicol. 2022; 164:113008. PMC: 9012513. DOI: 10.1016/j.fct.2022.113008. View

17.

Furer V, Rondaan C, Heijstek M, Agmon-Levin N, van Assen S, Bijl M . 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2019; 79(1):39-52. DOI: 10.1136/annrheumdis-2019-215882. View

18.

Frenck Jr R, Klein N, Kitchin N, Gurtman A, Absalon J, Lockhart S . Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021; 385(3):239-250. PMC: 8174030. DOI: 10.1056/NEJMoa2107456. View

19.

Kampf G . The epidemiological relevance of the COVID-19-vaccinated population is increasing. Lancet Reg Health Eur. 2021; 11:100272. PMC: 8604656. DOI: 10.1016/j.lanepe.2021.100272. View

20.

Srivastava K, Carreno J, Gleason C, Monahan B, Singh G, Abbad A . SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. Immunity. 2024; 57(3):587-599.e4. PMC: 11066813. DOI: 10.1016/j.immuni.2024.01.017. View